LIVER INTERNATIONAL国际肝病
LIVER INTERNATIONAL(英文缩写 LIVER INT),ISSN 1478-3223,eISSN 1478-3231,中文译名:国际肝病 是一本学术期刊。本页汇总该期刊的最新影响因子、分区信息以及最新收录于 PubMed 的文献,帮助您快速了解期刊全貌。
发文量统计区间：2025-09-28 至 2026-09-28，按本站收录文献的发表日期统计。
期刊介绍
历年影响因子趋势
| JCR 数据年份 | 影响因子 | JCR 分区 |
|---|---|---|
| 2021 | 8.754 | Q1 |
| 2022 | 6.700 | Q1 |
| 2023 | 6.000 | Q1 |
| 2024 | 5.200 | Q1 |
| 2025 | 6.200 | Q1 |
LIVER INTERNATIONAL 最新收录文献
-
2. Comment on 'Comparison of Factors Associated With 30- and 90-Day Readmission Among a Global Cohort of Patients Hospitalised With Cirrhosis'.
PMID:期刊:日期:2026-10-01该文献暂无摘要。
-
3. A Genetic Risk Variant Associated With the Risk of Primary Biliary Cholangitis Is Inherited From Neanderthals.
PMID:期刊:日期:2026-10-01Primary Biliary Cholangitis (PBC) is an autoimmune cholangiopathy with polygenic architecture and unknown aetiology. Evidence links Neanderthal-derived genetic variants to autoimmune conditions; however, their contribution to PBC susceptibility remains unexplored. We investigate whether archaic alleles influence PBC risk. Genotype data from four PBC cohorts were analysed: CANUK (4615 cases, 9233 controls), OLD IT (444 cases, 901 controls), NEW IT (255 cases, 579 controls) and MAYO (891 cases, 621 controls). Association testing with 235 592 Neanderthal Informative Markers (NIMs) was performed, adjusting for population stratification. Heritability was estimated using RHE-mc and temporal haplotype dynamics were assessed using ancient DNA data from Europe and Asia. A Neanderthal-derived variant in TNPO3 (rs12531711), previously reported by Cordell et al. showed strong association in CANUK (p = 2.04 × 10) and replicated across all validation cohorts. This variant functions as an eQTL, upregulating IRF5 and downregulating TNPO3 in blood. It is rare in African populations but common both in Europeans and Asians. Temporal analysis of the haplotype carrying rs12531711 revealed frequency increased substantially during the Bronze Age (5000-3000 BP), rising from 2.0% to 7.7% in Europe and 3.4% to 17.4% in Asia, before stabilizing. Despite this strong single-variant association, the heritability explained by NIMs was not significantly different from that of non-NIM variants. A Neanderthal-derived variant contributes to PBC risk and its frequency increased in the Bronze Age, possibly due to pathogen-driven selection. Archaic introgression overall has limited influence on PBC heritability. Functional studies are needed to elucidate the role of rs12531711.
-
4. Diagnostic Value and Influencing Factors of Ultrasound-Derived Fat Fraction for Quantifying MASLD in Children.
PMID:期刊:日期:2026-10-01To evaluate the diagnostic performance of ultrasound-derived fat fraction (UDFF) for quantifying Metabolic dysfunction-associated steatotic liver disease (MASLD) in children, using Magnetic resonance imaging-derived proton density fat fraction (MRI-PDFF) as the reference standard. This prospective study enrolled 70 children with a median age of 12.23 years [IQR, 10.47-14.29] from December 2025 to April 2026. All participants underwent UDFF, MRI-PDFF, and point shear wave elastography (pSWE) examinations. Steatosis was defined as MRI-PDFF ≥ 6.4%. Correlations, agreement, diagnostic accuracy, and bias predictors were assessed using Pearson/Spearman correlation, Bland-Altman, ROC curves, and multivariable regression. Of 70 participants, 42 had MASLD. UDFF correlated strongly with MRI-PDFF (r = 0.84, p < 0.001). Overall mean bias was -2.19% (95% concordance limits: -15.07% to 10.68%), with a more pronounced systematic numerical bias observed in moderate-to-severe steatosis (mean bias -9.23%). No significant bias predictors were found. For detecting steatosis (≥ 6.4%), UDFF had an AUC of 0.98, optimal cutoff 5.5% (sensitivity 97.6%, specificity 92.9%, accuracy 95.7%); for ≥ S2 steatosis, the cutoff was 12.5% (AUC 0.96). Intraclass correlation for five repeated UDFF measurements was 0.98 (95% CI: 0.98-0.99). Visceral fat thickness (β = 2.004, p = 0.003) and measurement depth (β = 4.716, p = 0.033) independently predicted UDFF values. UDFF showed a weak negative correlation with pSWE Young's modulus (r = -0.258, p = 0.033). UDFF is a non-invasive, accurate, and reproducible tool for quantifying paediatric hepatic steatosis. Although a systematic numerical bias exists relative to MRI-PDFF in moderate-to-severe cases, UDFF retains excellent discriminative ability and is suitable for screening, staging, and longitudinal follow-up of paediatric MASLD.
-
5. {"_":"Cell Type-Specific Roles of TBK1 in Steatotic Liver Disease: Evidence for an Inflammatory TBK1CASP1 Kupffer Cell State.","sup":["+","+"]}
PMID:期刊:日期:2026-10-01该文献暂无摘要。
-
6. Applicability of Non-Invasive Eligibility Criteria for MASH Pharmacotherapy: A Multicentre Cohort Study.
PMID:期刊:日期:2026-10-01Non-invasive tests (NITs) are increasingly used to guide patient selection for pharmacological treatment of metabolic dysfunction-associated steatohepatitis (MASH). We aimed to quantify and compare real-world treatment eligibility according to the AASLD and expert panel-derived criteria and to evaluate classification of patients with available liver histology. We retrospectively included 897 adults with MASLD from four Italian referral centres. Eligibility was assessed using AASLD criteria, defined by liver stiffness measurement (LSM) 8-15 kPa without cirrhosis, and expert panel-derived criteria, defined by LSM 10-19.9 kPa, platelet count ≥ 140 × 10/L, and no cirrhosis. A subgroup of 175 patients underwent liver biopsy within ±3 months of first referral. Median age was 62 years, 57.1% were men, 48.4% had obesity, and 36.0% had Type 2 diabetes. Overall, 202 patients (22.5%) met AASLD criteria and 114 (12.7%) met expert panel-derived criteria. Eighty-six patients were eligible according to both criteria, whereas 144 were classified differently. Type 2 diabetes and obesity were independently associated with eligibility under both criteria. In the biopsy subgroup, 73 patients had histological F2-F3 fibrosis; 35 (47.9%) did not meet AASLD criteria and 49 (67.1%) did not meet expert panel-derived criteria. The AASLD and expert panel-derived criteria identified different real-world populations potentially suitable for MASH pharmacotherapy. In the biopsy subgroup, NIT-based eligibility classification only partly aligned with histological F2-F3 fibrosis.
-
7. Ultrasound-Based Skeletal Muscle Assessment for Prognostication in Cirrhosis: A Systematic Review.
7. 基于超声的骨骼肌评估在肝硬化预后判断中的应用：一项系统综述PMID:期刊:日期:2026-10-01Sarcopenia is a major determinant of adverse outcomes in cirrhosis, yet CT- and MRI-based assessments are difficult to implement in routine and longitudinal practice. Ultrasound is a feasible bedside alternative, but its prognostic role remains unclear. We performed a systematic review to evaluate the association between ultrasound-derived skeletal muscle measures and mortality in adults with cirrhosis. This review followed PRISMA guidelines and was registered in PROSPERO (CRD420251056162). MEDLINE, Scopus, Web of Science and the Cochrane Library were searched to October 2025. Prospective studies assessing ultrasound-based muscle parameters and mortality in cirrhosis were included. Risk of bias was evaluated using QUIPS. Six prospective studies (n = 731) were included. Heterogeneity in muscle sites, ultrasound protocols, indexation methods, sarcopenia definitions and outcomes precluded meta-analysis. Lower ultrasound-derived muscle measures were consistently associated with higher mortality. In acute decompensation, reduced rectus femoris area predicted 90-day mortality (sHR 0.57; 95% CI 0.38-0.85). Rectus abdominis thickness and psoas indices were also associated with mortality. In hospitalized decompensated cirrhosis, ultrasound-defined sarcopenia was strongly associated with 6-month mortality (HR 6.37; 95% CI 3.15-12.87). In critically ill liver transplant candidates, higher serial rectus femoris muscle area measurements were associated with better survival. In advanced chronic liver disease, sarcopenia was linked to increased 1-year mortality. In our systematic review, ultrasound-based muscle measures demonstrated a broadly consistent association with mortality; although not yet fully validated, they represent a promising bedside prognostic tool. Standardization is needed before clinical implementation.
-
8. BBOX1 Deficiency Exacerbates Liver Fibrosis Through Carnitine Biosynthesis Disruption Rescued by Carnitine Supplementation.
PMID:期刊:日期:2026-10-01Liver fibrosis is a major global health burden with limited treatments. Emerging evidence suggests that metabolic dysregulation can create a state that makes the liver more prone to fibrosis. Carnitine, synthesized by γ-butyrobetaine hydroxylase (BBOX1), is crucial for fat metabolism, but the role of the BBOX1-carnitine axis in liver fibrosis is unclear. This study aimed to elucidate the functional impact of BBOX1 deficiency on hepatic fibrogenesis and to delineate the underlying mechanistic pathway. We analysed human liver transcriptomic data. Bbox1 knockout (KO) mice and wild-type (WT) littermates were subjected to thioacetamide (TAA)-induced liver fibrosis, with or without dietary L-carnitine supplementation. Comprehensive analyses included metabolomic and transcriptomic profiling, histopathological evaluation, and focused investigation of calcium-dependent signalling pathways. BBOX1 expression was significantly downregulated in human cirrhotic livers and correlated with reduced systemic carnitine levels. Bbox1-KO mice exhibited profound hepatic carnitine depletion and a metabolically primed state. With TAA challenge, KO mice developed exacerbated liver fibrosis and inflammation compared to WT controls. This susceptibility was driven by the aberrant activation of the TRPC6-Ca/CAMK2B-inflammatory signalling axis. Moreover, dietary L-carnitine supplementation completely rescued the aggravated fibrotic phenotype in KO mice. BBOX1 is a key regulator of liver carnitine metabolism. Its deficiency creates a pro-fibrotic state by abnormally activating the TRPC6-Ca/CAMK2B pathway. Our findings position carnitine as a protector of calcium balance in the liver and identify L-carnitine supplementation as a potential targeted treatment to slow fibrosis progression.
-
9. Sex Disparities in Hepatitis C Treatment Initiation: Role of Universal Access to DAA in France (ANRS FANTASIO 2).
PMID:期刊:日期:2026-10-01Ensuring access to direct-acting antivirals (DAA) for all individuals concerned is a priority in hepatitis C elimination efforts. We analysed sex disparities in DAA initiation in France over a 9-year period spanning before and after August 2017, when the country implemented universal DAA access. We used data from the French National Health Data System for two periods: 2014-2017 and 2017-2022. Socioeconomic and clinical characteristics of adults identified with chronic hepatitis C and residing in metropolitan France were described at each period entry date. DAA initiation incidence rates were then estimated and multivariable Cox proportional hazards models were used to identify potential sex disparities for each period. The study population comprised 97 817 and 98 020 individuals (61.3% and 62.0% men) before and after universal access to DAA, respectively. Comorbidity prevalence was significantly lower among women, except for psychiatric disorders. Compared with men, the incidence rate of DAA initiation was lower in women before universal access (24.5 [24.2-24.9] vs. 26.1 [25.8-26.3] per 100 person-years (PY), p < 0.001), and higher after (22.3 [21.9-22.6] vs. 18.5 [18.3-18.7] per 100 PY, p < 0.001). These differences were confirmed in multivariable models. In France, universal DAA access has reversed sex disparity in treatment initiation among people with chronic hepatitis C. This reversal likely reflects differences in disease progression profiles between men and women. To ensure truly equitable access to HCV care, current research should explore whether reversal or reduction of sex disparities is observed in other countries and subpopulations.
-
10. Multicenter Evaluation of Large Language Models Versus Hepatologists for Prognostic Prediction in Drug-Induced Liver Injury.
PMID:期刊:日期:2026-10-01Drug-induced liver injury (DILI) would progress to chronicity or death. Large language models (LLMs) may enhance clinical decision-making, yet their utility relative to physicians in DILI remains unclear. Therefore, we evaluated their performance in predicting DILI outcomes. We enrolled 943 DILI patients from three centers as internal and external cohorts. Based on 12-month follow-up, outcomes were classified as recovery, 6/12-month chronicity, and death. LLMs (Gemini-2.5 Pro, GPT-5.1, DeepSeek-3.2), hepatologists (Junior, middle, senior), and models (Hy's Law, nHy's Law, MELD Score) estimated probabilities of outcomes. LLM-Rules (VOTE, OR, AND) were applied to enhance stability. Model performance was assessed. For 6-month chronicity, the senior achieved highest AUROC (0.61) with an accuracy of 70%. Gemini-2.5 Pro and GPT-5.1 yielded AUROCs of 0.60 and 0.59, respectively, outperforming junior and middle hepatologists. Gemini-2.5 Pro demonstrated strongest agreement with senior (κ = 0.43). LLMs all exhibited lower accuracy and specificity than hepatologists. A similar result was observed in 12-month chronicity. For overall mortality, the senior achieved highest AUROC (0.87) with an accuracy of 83%. Gemini-2.5 Pro and GPT-5.1 achieved AUROCs of 0.86, outperforming junior hepatologist, Hy's Law, and nHy's Law. GPT-5.1 achieved strongest agreement with senior (κ = 0.25). LLM-Rules demonstrated stability for predicting outcomes across cohorts. OR and AND rules improved sensitivity and specificity, respectively. GPT-5.1 and Gemini-2.5 Pro showed AUROCs approaching senior hepatologists for DILI outcomes with limited accuracy and specificity. LLM-Rules demonstrated stable performance across cohorts with improved sensitivity or specificity, supporting the potential of multi-LLM approaches as clinician-supervised complementary tools.